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The anti-Helicobacter pylori (H. pylori) activities of dichloromethane and methanol extracts 
of Myristica fragrans Houtt. seed (nutmeg) was studied to authenticate traditional use in 
gastrointestinal disorder. Anti-H. pylori activities using the agar dilution method was investigated in 
39 strains of H. pylori comprising 38 clinical isolates and a standard strain. Bactericidal studies 
were done by the viable counting technique. The effct of 500 mg/kg and 250 mg/kg body weight of 
the methanol extract of nutmeg on H. pylori-induced gastritis and colonization was investigated in 
albino rats. The minimum inhibitory concentration (MIC) was 6.25 mg/mL while the minimum 
bactericidal concentration (MBC) ranged from 6.25 mg/ L to 100 mg/mL. Bacterial density score 
of the gastric mucosa reduced from 5.0 ± 7.07 x 108  to 1.6 ± 1.4 x 104 and 3.45 ± 1.4 x 104 CFU/mL 
(mean ± SD, p < 0.05) after treatment with 500 mg/kg body weight and Ofloxacin 400 mg/kg 
respectively. Analysis of variance (ANOVA) tested the effect of the groups on the treatment days 
and revealed a significant difference between the treatments at p< 0.05. The results of these studies 
have proven the activities of Myristica fragrans Houtt. seed on H. pylori - induced gastritis in albino 
rats.  
© 2014 International Formulae Group. All rights reserved. 





Helicobacter pylori (H. pylori) 
infection is an important etiologic impetus 
usually leading to chronic gastritis, 
gastroduodenal ulcer and low grade gastric 
mucosa associated lymphoid tissue 
lymphoma. Epidemiological data shows that a 
high H. pylori infection rate is related to the 
high incidence of gastric cancer and gastric 
adenocarcinoma (Forman and Burley, 2006).  
The World Health Organization through the 
International Agency for Research on Cancer 
in 1994 recognized H. pylori as a class 1 
carcinogen and it is now recognized as a 
primary bacterial gastric pathogen in humans 
(Blaser and Atherton, 2004). The incidence of 
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infection by Helicobacter pylori in human 
varies with age and socioeconomic condition, 
however, symptomatic H. pylori gastritis 
occurs with high frequency in the Western 
World (Perez-Perez et al., 2005). H. pylori 
infection is common worldwide with 
prevalence rates ranging from 30 to 40% in 
the United States, 80 to 90% in South 
America and 70 to 90% in Africa (Ndububa et 
al., 2001; Genta, 2002; Perez-Perez et al., 
2005; Tsai et al., 2005). A very high 
prevalence of H. pylori (88.9%) in South 
West, Nigeria has been reported (Adeniyi et 
al., 2012). A recent trend in therapeutic 
regimens for H. pylori eradication is adoption 
of a triple therapy with proton pump inhibitor 
and two antimicrobials-amoxicillin and 
clarithromycin. However, the occurrence of 
strains resistant to clarithromycin has given 
rise to concern, and this problem might be of 
particular importance in areas where many 
people are infected with H. pylori (Wang et 
al., 2005).  Therefore, it is important to search 
for non-antibiotic substances, which are 
highly safe in terms of gastrointestinal 
protection from H. pylori-associated diseases. 
       Myristica fragrans Houtt. (nutmeg) is 
used as a cure for headache and as a 
gastrointestinal drug in the Indian ancient 
Ayurveda; and has been used for dyspepsia, 
bellyache, diarrhoea and vomiting in the 
traditional Chinese medicine. Myristica 
fragrans has reportedly been used as a fruit 
paste and applied to teeth. Extracts of M.
fragrans have been reported to have 
antimicrobial activity against Escherichia coli, 
Salmonella, and other bacteria not typically 
found in the mouth, and not known to have 
any implication in causing plaque or gingivitis 
(Indu, 2006). In traditional medicine, the seed 
kernel (nutmeg) is widely used as carminative, 
astringent, hypolipidaemic, antithrombotic, 
antiplatelet aggregation, antifungal and 
aphrodisiac (Sonavane et al., 2002). It is also 
used in the treatment of flatulence, nausea, 
and dyspepsia (Zaidi et al., 2009). In Nigeria, 
nutmeg is used as culinary spices and 
preservatives in snacks production. While 
some researchers have reported the in vitro 
anti- H. pylori activity of nutmeg (Mahady et 
al., 2005; O’Mahony et al., 2005), the 
medicinal purpose most especially for 
gastrointestinal disorder has not been 
investigated in Nigeria, hence the importance 
of this study. In addition H. pylori-induced 
gastritis in albino rat model has not also been 
investigated in Nigeria.  
 
MATERIALS AND METHODS  
Plant collection, extraction, and 
preparation of extracts 
The seed of Myristica fragrans Houtt. 
(nutmeg) was obtained at Bodija Market, 
Ibadan, Nigeria and authenticated at the Forest 
Research Institute of Nigeria (FRIN), Ibadan 
and at the Department of Botany, University 
of Ibadan, Ibadan, Nigeria. The plant sample 
was air-dried and then meshed prior to 
extraction. The plant material (3 kg) was 
subjected to exhaustive Soxhlet extraction 
with methanol. Partitioning of the extracts 
with n-hexane and dichloromethane based on 
their polarity was done to have three different 
fractions: n-hexane, dichloromethane and 
methanol fractions. The resulting extracts 
were concentrated to dryness under reduced 
pressure, weighed, lyophilized and stored at 4 
oC. Ten grams (10 g) of each extracts 
reconstituted with 20% ethanol to obtain the 
stock solutions which were further diluted to 
final concentrations of 100, 50, 25, 12.5, 6.25 
and 3.125 mg/ml were used for the in vitro 
susceptibility testing against the various H.
pylori strains. For the animal studies, 50 
grams of the extracts were prepared to final 
concentrations of 500 and 250 mg/kg body 
weight. 
 
Phytochemical screening of extracts 
Phytochemical screening was carried 
out to detect the presence of secondary 
metabolites such as anthraquinones, tannins, 
saponins, alkaloids, and phenols using 
methods described by (Harborne, 1998). 
 
In vitro susceptibility testing  
The susceptibility and minimum 
inhibitory concentration (MIC) testing were 
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performed using the agar dilution procedure 
guidelines of the Clinical and Laboratory 
Standards Institute (CLSI, 2008). The medium 
used was Mueller-Hinton agar supplemented 
with 5% defibrinated horse blood. The final 
concentrations of the extracts tested were 100, 
50, 25, 12.5, 6.25 and 3.125 mg/mL for each 
sample. A total of 38 clinical isolates and a 
standard strain ATCC 43504 of H. pylori were 
used in the susceptibility testing. The 
identification of each organism has been 
confirmed by Gram stain appearance and a 
positive urease test. Ofloxacin at a 
concentration of 10 µg/mL was used as 
positive control. MacFarland 2 suspensions of 
H. pylori strains were prepared in Tryptic soy 
broth from 4–5 days old H. pylori on blood 
agar (Adeniyi et al., 2009). The organisms 
were inoculated onto agar plates containing 
the plant extracts via a graduated inoculating 
device which delivers two hundred microlitre 
(200 µL) per spot. The spots were air-dried 
before incubating the plates at 37 oC under a 
microaerophilic gas mixture composed of 
10% CO2, 5% O2, and 85% N2 (Campygen, 
Oxoid, UK) at 100% humidity and examined 
for growth after 5 days. All procedures were 
repeated for accuracy. The least concentration 
that gave no visible growth was taken as the 
minimum inhibitory concentration (MIC) of 
the extract. The minimum bactericidal 
concentration (MBC) testing was performed 
as previously described by (Adeniyi et al., 
2009; Aibinu et al., 2007). The lowest 
concentration that prevented bacterial growth 
after days of incubation was recorded as the 
minimum bactericidal concentration (MBC). 
The bactericidal activity was performed using 
viable counting techniques previously 
described (Ogudo et al., 2014). 
 
In vivo studies: albino rat model 
Animal 
Specific pathogen-free male albino rats  
(Central animal house, College of Medicine, 
University of Ibadan, Nigeria) 6-8 weeks old, 
were housed in plastic cages with hard wood 
chips in an air-conditioned biohazard room for 
infection with a 12 hours light-12 hours dark 
cycle. They were given food (Ladokun & 
Sons pelletized rat feeds, Ibadan, Oyo State, 
Nigeria) and water in bottles ad libitum.  
Bacterial inoculation 
 H. pylori BAA 037 susceptible to 
methanol extract of M. fragrans in vitro was 
grown in Tryptic soy broth (Oxoid, UK) and 
cultured on Mueller Hinton agar (Oxoid, UK) 
containing 5% V/v horse blood at 37oC in a 
microaerophilic gas mixture composed of 
10% CO2, 5% O2, and 85% N2 (Campygen, 
Oxoid, UK) at 100% humidity. After each rat 
had fasted for 24 hours, 0.8 mL sample 
containing 1×109 colony-forming units (CFU) 
per milliliter (1×109 CFU/mL) of H. pylori 
was used as the inoculum and delivered via 
the oral canular. 
Extract preparation 
Lyophilized methanol extract of M. 
fragrans Houtt. (nutmeg), was reconstituted in 
20% ethanol to final concentrations equivalent 
to 250 mg/kg body weight and 500 mg/kg 
body weight of rats. 
Experimental protocol 
 Thirty-three (33) albino rats were 
divided into five groups. Group A and B were 
the treatment groups and were given 500 
mg/kg (Group A, n= 9) and 250 mg/kg (Group 
B, n= 9) body weight of methanolic extract of 
Myristica fragrans 12 hourly. Group C (n=5) 
served as positive (drug) control and received 
H. pylori challenge and given 400 mg/kg body 
weight of Ofloxacin 24 hourly. Group D 
(n=5), the negative control group received H. 
pylori - challenge but no treatment. Group E 
(n=5) did not receive the treatment nor H.
pylori challenge. At 8-10 weeks of age, all 
animals except Group E were fasted for 24 
hours and then inoculated with H. pylori BAA 
037 by gavage (0.8 mL, 1.0 × 109 
CFU/animal). The infected groups (A - D) 
were given standard diet and water alone for a 
week to allow colonization and establishment 
of infection in the gastric mucosa. From day 
one till the end of the experimental period, 
body weights of the rats were measured once 
a week and animals were monitored daily for 
their general health.  After a week of 
infection, rats from groups A, B and C were 
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sacrificed and the stomach excised. The 
excised stomachs were cut open along the 
greater curvature and then were divided in 
half along the lesser curvature. One half was 
used for a culture study while the other was 
used for histopathological analyses to 
ascertain the establishment of infection. This 
procedure was carried out one week and two 
weeks after treatment to monitor the effect of 
the extract on Helicobacter pylori and 
gastritis. The excised stomach (half) was 
homogenized with 5 mL of Tryptic soy broth 
with the help of vortex mixer and then diluted 
serially from 1: 10 (10-1) to 1: 1000000 (10-6). 
Aliquots (100 µL) of the dilution was 
inoculated onto Columbia agar (Oxoid, UK) 
plates supplemented with 5% horse blood  and 
incubated under microaerophilic condition 
and high humidity for 3 to 5 days. After 5 
days the colonies were counted to determine 
the level of H. pylori colonization and effect 
of treatment. Colonies were identified as H. 
pylori based on their characteristic 
morphology. The density of H. pylori was 
assessed as CFU per whole stomach. This was 
carried out at a week after infection, week 1 of 
treatment and 2 weeks after treatment. The 
other half was fixed in 10% neutral buffered 
formalin for histopathological examination. 
The effect of treatment was evaluated using 
the Updated Sydney System which was 
reported as severe, moderate and mild. 
 
Statistical analysis 
Analysis of variance (ANOVA) tested 
the effect of the extract in animal groups on 
the treatment days and it revealed a significant 
difference between the treatments at p< 0.05. 
The possibility of the methanol extract of 
Myristica fragrans reducing H. pylori load 
and thus effecting healing of the gastritis was 
compared with effect of the control drug- 




In vitro susceptibility  
The crude methanol extract of nutmeg 
was phytochemically screened for the 
presence of secondary metabolites; the result 
revealed the presence of alkaloids, 
anthraquinones, flavonoids, tannins and 
phenols. The dichloromethane extract 
inhibited the growth of four out of the thirty-
nine H. pylori isolates tested in vitro with 
MIC value of 6.25 mg/mL and MBC values of 
6.25 mg/mL- 12.5 mg/mL (Table 1). H. pylori 
BAA 037 was the only strain susceptible to 
methanol extract of M. fragrans with MIC and 
MBC values of 25 mg/mL and 100 mg/mL 
respectively. Bactericidal studies (kill 
kinetics) of the extracts on  the H. pylori 
isolates revealed a drastic dose dependent 
decline in the surviving population after 8 
hours of exposure to the extract at doses 
equivalent to MIC, 2 x MIC and 4 x MIC, 
accompanied with a total kill of the population 
at 24 hours (Figures 1-3). 
 
Effects in Albino rats  
The in vivo study investigated the 
possibility of H. pylori colonizing the gastric 
mucosa of albino rats and eliciting infection 
(gastritis) and also if the treatment with 
different concentrations of methanol extract of 
nutmeg seed would have effect on the H. 
pylori-induced gastritis. It was noted that H.
pylori was able to colonize and elicit infection 
in rat model (gastritis); and that the extract 
reduced the microbial load and had effect on 
the induced gastritis. The results of this 
experiment are shown in Table 2 and Figures 
4-8. In Groups A, B, C and D all the animals 
inoculated with H. pylori were infected and 
developed severe gastritis. The submucosal 
layer was very prominent, appears severely 
congested and haemorrhagic after 7 days of 
infection (Figure 4). In Group A (infected 
animals treated with 500 mg/kg body weight 
of methanol extract of Myristica fragrans) 
there was a moderate cellular infiltration and 
congestion at the lamina propria/submucosal 7 
days post-treatment, followed by a mild 
cellular infiltration after 14 days of treatment 
(Figure 5). In group B (infected animals 
treated with 250 mg/kg body weight of 
methanol extract of Myristica fragrans); there 
was a large extensive focus of severe 
submucosal and epithelial necrosis as well as 
cellular infiltration by mononuclear cells after 
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7 days of treatment. There was no visible 
lesion seen after 14 days of treatment. Group 
C (infected animals treated with 400 mg/kg 
body weight of Ofloxacin) showed a moderate 
to severe cellular infiltration at the laminar 
propria with few extending to the mucosal 
glands after 7 days of treatment and  moderate 
cellular infiltration and congestion at the 
laminar propria/submucosal after 14 days of 
treatment (Figure 6). Group D had severe 
congestion, dispersal of the submucosal 
connective tissue, with severe cellular 
infiltration by mononuclear cells. The basal 
region of the epithelial glands was also 
congested; there was a focus of epithelial 
erosion after 21 days of infection without 
treatment (Figure 7). Group E was the control, 
normal stomach in which there was no visible 
lesion seen (Figure 8). The H. pylori load in 
Group A animals (treated with 500 mg/kg 
body weight of methanol extract of Myristica 
fragrans) was significantly reduced from 5.0 
± 7.07 × 108 CFU/mL to 2.7 ± 1.4 × 104 
CFU/mL and 1.6 ± 1.4 × 104 CFU/mL on days 
7 and 14 respectively compared to Group C 
animals (infected animals treated with 400 
mg/kg body weight of Ofloxacin) which had a 
microbial load reduction from 5.0 ± 7.07 × 
108 CFU/mL to 4.65 ± 1.4 × 104 CFU/mL and 
3.45 ± 1.4 × 104 CFU/mL on days 7 and 14 
respectively (Table 2). Importantly, the extract 
did not increase morbidity or mortality of the 




Table 1: Minimum inhibitory concentrations (MIC) and minimum bactericidal concentration 
(MBC) of lyophilized extracts of Myristica fragrans Houtt. (nutmeg) seed on susceptible H. pylori 
isolates. 
 
H. pylori Methanol extract           




MIC MBC MIC MBC MIC MBC 
 BAA 025 R R 6.25 12.5 10 40 
 BAA 037 25 100 R R 10 40 
 BAA 044 R R 6.25 6.25 120 120 
 BAA 049 R R 6.25 12.5 7.5 30 
 BAA 050 R R 6.25 12.5 30 30 
           Note: R = Resistance (i. e. no activity of the extrac s) 
 
 
Table 2: Effect of methanol extract of Myristica fragrans Houtt. (nutmeg) on Helicobacter  pylori 
colonization in the gastric mucosa of albino rats at day 7 and 14 of treatment. 
 
Group Density of H. pylori in 
the gastric mucosa 
before treatment 
(CFU/mL ) 
Density of H. pylori in 
the gastric mucosa 
after treatment- Day 7 
(CFU/mL) 
Density of H. pylori in 
the gastric mucosa 
after treatment- Day 14 
(CFU/mL) 
A 5.0 ± 7.07 × 108a 2.7 ± 1.4 × 10
4 b 1.6 ± 1.4 × 10
4
c 
B 5.0 ± 7.07 × 108a 5.75 ± 1.4 × 10
4
b 5.65 ± 1.4 × 10
4
c 
C 5.0 ± 7.07 × 108a 4.65 ± 1.4 × 10
4
b 3.45 ± 1.4 × 10
4
c 
Means with different subscripts along the same row are significantly (p< 0.05) different; Note: The result is mean ± S.D (p< 
0.05). Group A- H. pylori challenged treated with 500 mg/kg body weight of nutmeg extract; Group B- H. pylori challenged 
treated with 250 mg/kg body weight of nutmeg extract; Group C- H. pylori challenged treated with 400 mg/kg body weight 
of Ofloxacin (positive control). 
 
 




Figure 1: Percentage viable count (Survival) vs Time (hour) of dichloromethane extract of 








Figure 2: Percentage viable count (Survival) vs Time (hour) of dichloromethane extract of 








Figure 3: Percentage viable count (Survival) vs Time (hour) of methanol extract of Myristica 






Figure 4: Groups A-D; H. pylori- infected stomach before treatment- The submucosal layer is very 
prominent (longer arrows), and appears severely congested and haemorrhagic (shorter arrows). M x 
100, Hematoxylin & Eosin. 
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Figure 5: Group A (H. pylori challenged treated with 500 mg/kg body weight of nutmeg extract) A. 
Day 7 of treatment- There is a moderate cellular infiltration and congestion at the laminar 
propria/submucosal. B: Day 14 of treatment- There is a very mild cellular infiltration at the lamina 
propria/submucosal. M x 100, Hematoxylin & Eosin. 
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Figure 6: Group C (H. pylori challenged treated with 400 mg/kg of Ofloxacin) - A. Day 7 of 
treatment - There is no visible lesion seen. B: Day 14 of treatment- There is no visible lesion seen. 
M x 100, Hematoxylin & Eosin. 




Figure 7: Group D (negative control group received H. pylori - challenge but no treatment) - There 
is severe congestion, dispersal of the submucosal cnnective tissue, with severe cellular infiltration 
by mononuclear cells (longer arrows). The basal regions of the epithelial glands are also congested 





Figure 8: Group E- Normal stomach (receive neither treatment nor H. pylori challenge). There is no 
visible lesion seen. M x 100, Hematoxylin & Eosin. 
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DISCUSSION 
       In Nigeria Myristica fragrans Houtt. 
(nutmeg) is used for culinary purpose and as 
preservatives in snacks production. It is 
known as a cure for headache and as a 
gastrointestinal drug in the Indian ancient 
Ayurveda, and has been used for dyspepsia, 
bellyache, diarrhoea and vomiting in the 
traditional Chinese medicine (Jaiswal, 2011). 
In vitro susceptibility testing of M. fragrans 
on Helicobacter pylori (H. pylori) has been 
reported (Mahady et al., 2005; O’Mahony et 
al., 2005). This study investigated the anti-H. 
pylori activity and gastroprotective ability of 
M. fragrans in Nigeria and also to create a rat 
model to understand the pathogenesis of H. 
pylori-induced gastritis. The present study 
showed the in vitro and in vivo effects of 
nutmeg extracts on H. pylori-induced gastritis 
in albino rat model. Both culture and 
histopathological examinations revealed a 
clear reduction in the H. pylori colonization as 
well as reduced mucosal inflammation and 
epithelial proliferation in the stomach of H. 
pylori-infected rats (Table 2 and Figure 5).  
The activity of Myristica fragrans in reducing 
H. pylori load and thus effecting healing of 
the gastritis compared favourably well with 
the control drug (Ofloxacin) which would 
have been expected to have better activity 
being a pure drug. There are several animal 
models available to help understand the 
pathogenesis of H. pylori infection, including 
gnotobiotic piglets, athymic mice and 
monkeys (Poutahidis et al., 2001; Raghavan et 
al., 2003; Kodama et al., 2005). Other studies 
have reported animal model of H. pylori such 
as induction of ulceration and severe gastritis 
in Mongolian gerbil by H. pylori infection 
(Ohkusa et al., 2003), suppression of H.
pylori-induced gastritis by green tea extract in 
Mongolian gerbil (Ishizone et al., 2007), 
among others. However, there are no reports 
found on rat model H. pylori-induced gastritis 
as at the time this research was carried out. It 
is therefore interesting to report that rat model 
could also be used to understand the 
pathogenesis of H. pylori and that rat model 
could as well mimic human body in addition 
to previously reported animal models. 
Although nutmeg has been reported to 
demonstrate anti-H. pylori activity in vitro 
(Mahady et al., 2005; O’Mahony et al., 2005), 
there are no reports on anti- H. pylori activity 
of nutmeg in vivo. 
       In addition, the in vitro experiment 
revealed a broad antibacterial spectrum of 
nutmeg extracts including activity against 
some restricted organisms such as H. pylori. 
However, it did not demonstrate any 
antibacterial activity against Escherichia coli 
and Klebsiella pneumoniae tested in our 
preliminary study. Escherichia coli and 
Klebsiella pneumoniae are well known human 
intestinal flora. These safety characteristics of 
nutmeg may therefore be appropriate for its 
use in prevention of H. pylori infection. 
Chronic inflammation and increased cell 
proliferation are features common to the 
pathogenesis of many human cancers, and as 
these features seem to play a central role in 
the initiation and promotion of carcinogenesis 
(Ishizone et al., 2007); the reduction of 
inflammation and cell proliferation by nutmeg 
may thus be an effective modality for 
preventing H. pylori-induced carcinogenesis 
in the stomach.  
 
Conclusion 
The in vitro and in vivo studies have 
proven the anti-H. pylori activity of nutmeg 
and the ability of H. pylori to induce gastritis 
in albino rats. The development of the albino 
rat model for in vivo studies will enhance 
researches focused on the discovery and 
development of new and effective therapeutic 
agents from medicinal plants for the treatment 
of H. pylori infections especially in the 
developing world where the majority of the 
population depends on herbal remedies for 
cure. They also proved the anti-H. pylori and 
anti-inflammatory potential of M. fragrans 
(nutmeg). Hence nutmeg could serve as a 
good lead in the development of therapeutic 
agent for the treatment of H. pylori-associated 
infections. Since nutmeg serves culinary 
purposes, intake as food supplements could 
help alleviate or prevent H. pylori-associated 
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diseases. Further researches will focus on 
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